Violation Tracker Individual Record
Novartis Pharmaceuticals Corporation agreed to pay over $642 million in separate settlements resolving claims that it violated the False Claims Act. The first settlement pertained to the company's alleged illegal use of three foundations as conduits to pay the copayments of Medicare patients taking Novartis's drugs Gilenya and Afinitor. The second settlement resolved claims arising from the company's alleged payments of kickbacks to doctors. A portion of the total went to the states to resolve litigation brought by attorneys general (see separate entry).